Shares of genedrive (LON: GDR) initially spiked higher on Wednesday after the company provided an update on its Antibiotic Induced Hearing Loss assay.
Genedrive said they and Inspiration Healthcare Group, the distribution partner for the AIHL assay, believe new guidance in the UK on the importance of the management of specific genetic mutations and their role in hearing loss as a result of antibiotics will lead to increased demand for the genedrive AIHL test in the UK.
The new guidance follows an 11-month implementation trial at Manchester University, NHS Foundation Trust, and Liverpool Women’s Hospital, which concluded in November 2020.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The launch of the Genedrive AIHL assay remains on track for summer 2021.
The company is conducting an initial stage critical opinion leader engagement in the UK alongside Inspiration Healthcare in preparation for the commercial launch.
“Despite the emergence of COVID-19, our clinical partners showed huge dedication in keeping this important project on-track, becoming the first in the world to generate valuable information on the utility of this approach in an emergency care setting,” Commented David Budd, CEO of genedrive.
“As we see updated guidance and greater awareness to the requirement for genetic testing, we only expect increased interest in our novel assay,” genedrive’s CEO added.
After initially rising to 133p per share, genedrive’s stock price now trades at 127p, up 1.80% from Tuesday’s close.
Should you invest in Genedrive shares? Genedrive shares are traded on the AIM market of the London stock exchange (the alternative investment market) which is the sub market specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Genedrive shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
